Previous 10 | Next 10 |
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at t...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595 Serg...
2024-01-18 17:18:25 ET More on Ikena Oncology Ikena tumbles after early data for lead asset, Q3 financials Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology For f...
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources fro...
2023-12-15 08:46:33 ET Aurora Technology Acquisition ( ATAK ) +50% . Brilliant Acquisition ( BRLI ) +27% . Ikena Oncology ( IKNA ) +24% . SportsMap Tech Acquisition ( SMAP ) +14% . Pineapple Financial ( PAPL ) +1%...
2023-11-09 12:48:14 ET Gainers: Intelligent Bio Solutions ( INBS ) +149% . Pineapple Financial ( PAPL ) +87% . Ramaco Resources ( METC ) +34% . Tempest Therapeutics ( TPST ) +30% . Fitell Corp ( FTEL ) +32% . Honest Company (...
2023-11-09 12:18:43 ET More on Ikena Oncology Ikena Oncology a new buy at Wedbush on cancer asset with new target Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
News, Short Squeeze, Breakout and More Instantly...
Ikena Oncology Inc. Company Name:
IKNA Stock Symbol:
NASDAQ Market:
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...